A number of pharmaceutical firms have commented on US President Donald Trump’s demand to chop drug costs and impose tariffs, citing “excessive volatility” however signalling willingness for “constructive” cooperation.
Trump final week instructed main pharmaceutical corporations to decrease costs within the US or face penalties, aiming to deliver reduction to Individuals dealing with far greater drugs prices than in different nations.
“We proceed to look at excessive volatility,” Bayer CEO Invoice Anderson commented on the US commerce coverage, including that it stays unclear whether or not ongoing investigations within the sector will result in further pharma tariffs.
He additionally commented on Trump’s announcement that tariffs on prescription drugs may attain 250% within the coming years, meant to push firms to relocate manufacturing to the US.
“It is exhausting to take a position about what the influence could be subsequent yr till we’ve a extra concrete image of precisely what the commerce coverage shall be,” he added.
Pfizer CEO Albert Bourla stated his firm is in “very energetic discussions” over Trump’s request regarding most-favoured-nation pricing, in accordance with information web site FiercePharma. Bourla stated he had personally spoken to the president however didn’t share many particulars.
German pharmaceutical firm Boehringer Ingelheim issued an announcement on Tuesday, putting a equally constructive tone:
“We are going to proceed to work constructively with governments, regulatory authorities, and affected person organizations to make sure that sufferers have entry to reasonably priced medicines and that medical innovation for life-saving therapies stays potential.”
Regeneron CEO Leonard Schleifer additionally commented on the letters, agreeing with Trump that European nations usually are not paying their justifiable share for medication.
“The answer isn’t merely to decrease costs within the US with out some balancing adjustment in Europe, as a result of in any other case there shall be no innovation,” Schleifer stated.
(cs, de)
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our publication, and be part of our rising neighborhood at nextbusiness24.com
